Undoubtedly, plastic surgery is on the rise. Americans spent more than $16 billion on cosmetic plastic surgeries and dermal fillers in 2016 – the highest this figure has ever been. Plastic surgery is safer, more accessible, and more acceptable than ever before. Recently, the FDA approved a new facial filler: Juvéderm Vollure™ XC.
Juvéderm Vollure™ XC is part of the Voluma family of dermal fillers, and is used for the correction of moderate to severe facial wrinkles and folds, including nasolabial folds. There are dozens of facial fillers on the market. In fact, there are several fillers in the Juvéderm family alone. What makes Juvéderm Vollure™ XC different? Unlike its predecessors, Juvéderm Vollure™ XC can last up to 18 months – nearly a year longer than most other facial fillers. Vollure, like Voluma, is specially cross-linked, making it less hydrophilic than other dermal filler families. This means it will not result in a “puffy” look later on.
How Does Juvéderm Vollure™ XC Work?
Juvéderm Vollure™ XC uses a special mixture of hyaluronic acid with a longer life span. This hyaluronic acid is a gel like substance that molds to your face and lifts sinking skin. The new technology is soft enough to frame your face, while still making a noticeable difference in lines, folds, and wrinkles. In fact, in a clinical trial, 59 percent of participants saw improvement in smile lines around the mouth for up to 18 months, 82 percent of patients said they were satisfied with results at six months, and 68 percent were still pleased at eight months.
In addition, the hyaluronic acid in Juvéderm Vollure™ XC produces less swelling and even shorter down time than other facial fillers. With results lasting up to 18 months, patients need less follow up injections and enjoy a more cost effective way to beautiful, younger looking skin.
To learn more about Juvéderm Vollure™ XC, or to schedule your consultation, please fill out the form on this page or call our Beverly Hills office at (310) 860-8915, or our Pasadena office at (626) 537-3737.